Generics - Biotechnology, Politics

Filter

Current filters:

BiotechnologyPolitics

Popular Filters

Pharma associations strongly support Senate bill on FDA User Fees sequestration exemptions

05-08-2013

In the USA last week, Mark Pryor (Democrat, Arkansas), chairman of the Senate Appropriations Subcommittee…

BiotechnologyFinancialGenericsLegalNorth AmericaPharmaceuticalPolitics

US FY 2014 budget continues push to curb patent settlements, shorten biologics exclusivity; a lawyer's view

12-04-2013

At first look, the US Food and Drug Administration appears to have fared rather well under President…

BiotechnologyGenericsNorth AmericaPatentsPoliticsRegulationResearch

Mixed industry views on Virginia's law on biosimilar substitutions

25-03-2013

A new law in the US state of Virginia signed into law last week by Governor Bob McDonnell - designed…

BiotechnologyGenericsLegalNorth AmericaPoliticsRegulation

US biotech giants lobbying to block biosimilars, NTY claims

31-01-2013

Some of the USA's biggest biotechnology companies are lobbying intensively to limit generic competition…

AmgenBiotechnologyGenentechGenericsNorth AmericaPoliticsRegulation

European governments' austerity pricing tactics support generic drug growth

09-07-2012

Government initiatives to cut health expenditure are likely to encourage sales of generic medications…

BiotechnologyEuropeGenericsMarkets & MarketingPoliticsPricing

A lot of user fee issues in USA

15-01-2012

2012 has only just begun, but the US Congress, the Food and Drug Administration and several health care…

BiotechnologyGenericsNorth AmericaPharmaceuticalPoliticsRegulation

Parexel

Parexel

Back to top